Akebia Therapeutics (AKBA) Change in Accured Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Change in Accured Expenses data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 26.56% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $47.8 million, a 848.48% increase from a year earlier, with the FY2025 full-year figure at $48.5 million, up 479.82% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $2.0 million, down from $13.9 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for AKBA reached as high as $16.0 million in Q2 2025 and fell as low as -$26.8 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$602235.3 across 5 years, with a median of $2.8 million in 2025.
• Across the five-year window, Change in Accured Expenses tumbled 440.04% in 2023 and jumped 2984.2% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$16.5 million in 2022, then surged by 122.55% to $3.7 million in 2023, then soared by 31.26% to $4.9 million in 2024, then jumped by 185.7% to $13.9 million in 2025, then plunged by 85.39% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $2.0 million in Q1 2026, $13.9 million in Q4 2025, and $15.8 million in Q3 2025.